|
Serotonergic Pharmacotherapy for Agitation of Dementia Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Serotonergic Pharmacotherapy for Agitation of Dementia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Serotonergic Pharmacotherapy for Agitation of Dementia Clinical research trials and Serotonergic Pharmacotherapy for Agitation of Dementia health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Serotonergic Pharmacotherapy for Agitation of Dementia. Serotonergic Pharmacotherapy for Agitation of Dementia Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Serotonergic Pharmacotherapy for Agitation of Dementia clinical trial. Subjects frequently get the best healthcare possible for their Serotonergic Pharmacotherapy for Agitation of Dementia condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Serotonergic Pharmacotherapy for Agitation of Dementia  Serotonergic Pharmacotherapy for Agitation of Dementia
Serotonergic Pharmacotherapy for Agitation of Dementia
For Condition: Dementia,Dementia, Vascular,Alzheimer Disease
Status: No longer recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
Details: The principal investigator is conducting an inpatient study at Western Psychiatric Institute and Clinic involving two medications for treatment of emotional and behavioral disturbances that may accompany dementia. In this study, 112 patients will be enrolled for up to 17 days in order to investigate the safety and effectiveness of both medications. Forty-two of these patients will be given a recently FDA-approved antidepressant medication called citalopram and 42 will receive one of our current, usual antipsychotic medications called perphenazine. An additional 28 patients will be given non-active placebo capsules. Which treatment a patient is given during the study will be determined by chance. Findings from this investigation may directly lead to the improvement of symptoms such as: agitation, hostility, suspiciousness, hallucinations, and unusual thoughts. Improved treatment of problematic behaviors and a decrease in medication-associated side effects would enable dementia patients to be cared for in their home environments for longer periods of time.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meets DSM-IV criteria for diagnosis of dementia of the Alzheimer's type (AD), Vascular dementia (VD), mixed (AD and VD) or dementia NOS (Not Otherwise Specified) - Presents with psychosis or behavioral problems severe enough to endanger the patient's health, well-being or safety, as evidenced by a score of at least 3 (moderate) on one of the Neurobehavioral Rating Scale (NBRS) agitation items (8,11,14) or psychosis items (16,18,20) and are not secondary to physical illness nor amenable to environmental optimization - Able to participate in study evaluations and ingest oral medication - Has next of kin or a guardian available to consent to patient's participation. Exclusion Criteria: - Has an unstable medical illness including significant cardiac (specifically bradycardia with ventricular rate below 50), renal, hepatic, or neurological illness (especially Parkinson's disease) other than dementia - Meets DSM-IV criteria for Delirium upon admission to Western Psychiatric Institute and Clinic - Has been medicated within 4 weeks of protocol admission with fluoxetine or 2 weeks with a monoamine oxidase inhibitor (patients will undergo a monitored psychotropic drug washout prior to entering the protocol) - Is currently being treated with cognitive enhancing drugs (Tacrine or Aricept) or any experimental drug - Has a concurrent diagnosis of schizophrenia, bipolar disorder, or major depression - Has preexisting orthostatic hypotension (with > 20 mmHg change from sitting to standing pressure)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BrucePollock, Principal Investigator, Western Psychiatric Institute and Clinic
University of Pittsburgh Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, 15213
United States
Additional Information:
Study ID Numbers: IA0014;
Study Start Date:
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00009204
Other Dementia, Vascular Studies:
1. Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease
2. Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder
3. ALADDIN Study
4. Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
5. Evaluation of Galantamine in the Treatment of Alzheimer's Disease
Related Studies:
Other Dementia, Vascular Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Serotonergic Pharmacotherapy for Agitation of Dementia
|
|
|
|
|
|
|
|
